CA3160636A1 - Methods and compositions for treating cancer - Google Patents

Methods and compositions for treating cancer

Info

Publication number
CA3160636A1
CA3160636A1 CA3160636A CA3160636A CA3160636A1 CA 3160636 A1 CA3160636 A1 CA 3160636A1 CA 3160636 A CA3160636 A CA 3160636A CA 3160636 A CA3160636 A CA 3160636A CA 3160636 A1 CA3160636 A1 CA 3160636A1
Authority
CA
Canada
Prior art keywords
antibody
seq
fragment
cancer
oxldl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3160636A
Other languages
English (en)
French (fr)
Inventor
Bertrand C. Liang
Stacey Ruiz
Christopher John Farina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abcentra LLC
Original Assignee
Farina Christopher John
Liang Bertrand C
Ruiz Stacey
Abcentra LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farina Christopher John, Liang Bertrand C, Ruiz Stacey, Abcentra LLC filed Critical Farina Christopher John
Publication of CA3160636A1 publication Critical patent/CA3160636A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3160636A 2019-11-12 2020-11-12 Methods and compositions for treating cancer Pending CA3160636A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962934078P 2019-11-12 2019-11-12
US62/934,078 2019-11-12
PCT/US2020/060309 WO2021097146A1 (en) 2019-11-12 2020-11-12 Methods and compositions for treating cancer

Publications (1)

Publication Number Publication Date
CA3160636A1 true CA3160636A1 (en) 2021-05-20

Family

ID=75912868

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3160636A Pending CA3160636A1 (en) 2019-11-12 2020-11-12 Methods and compositions for treating cancer

Country Status (7)

Country Link
US (1) US12570731B2 (cg-RX-API-DMAC10.html)
EP (1) EP4058042A4 (cg-RX-API-DMAC10.html)
JP (1) JP7722989B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220131222A (cg-RX-API-DMAC10.html)
CN (1) CN115003319B (cg-RX-API-DMAC10.html)
CA (1) CA3160636A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021097146A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
CN121102464B (zh) * 2025-09-19 2026-08-11 深圳市中佳生物医疗科技有限公司 一种小分子调节剂通过促进epc细胞分化改善aki治疗的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2500895A1 (en) * 2002-10-04 2004-04-15 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
GB0517878D0 (en) * 2005-09-02 2005-10-12 Bioinvent Int Ab Immunotherapeutic treatment
JP2010510772A (ja) 2006-11-27 2010-04-08 パトリス リミテッド 新生細胞における新規なグリコシル化ペプチド標的
AU2008296487A1 (en) 2007-08-28 2009-03-12 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
EP2240156A2 (en) 2007-12-28 2010-10-20 BioInvent International AB Antibody-containing formulation for the use for treating cardiovascular diseases associated with atherosclerosis
US20090311271A1 (en) 2008-05-29 2009-12-17 Wyeth Methods and Compositions for Selective Inhibition of Ligand Binding to the Lectin-Like Receptor for Oxidized Low Density Lipoprotein (LOX-1)
AU2010210312A1 (en) 2009-02-09 2011-08-04 Patrys Limited SAM-6 variants, target and methods of use
PE20120359A1 (es) 2009-03-06 2012-04-13 Genentech Inc Formulacion con anticuerpo
US8729240B2 (en) 2010-04-28 2014-05-20 National University Corporation Hokkaido University Monoclonal antibody against oxidized low-density lipoprotein
WO2011160845A2 (en) * 2010-06-24 2011-12-29 Medirista Biotechnologies Ab Oxidized phospholipids and lipoproteins, and antibodies thereto, as biomarkers of inflammatory conditions and methods of treatment
ES2773111T3 (es) 2011-09-16 2020-07-09 Regeneron Pharma Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a)
CN105358708B (zh) * 2013-03-14 2024-07-16 儿童医学中心公司 Cd36鉴定癌症对象以用于治疗的用途
US10858422B2 (en) * 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
WO2017210360A1 (en) * 2016-05-31 2017-12-07 Cardiovax, Llc Methods for diagnosing and treating systemic lupus erythematosus
EP3612563A1 (en) 2017-04-19 2020-02-26 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
WO2019210207A2 (en) 2018-04-27 2019-10-31 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor t regulatory cells for the treatment of atherosclerosis
WO2019232070A1 (en) * 2018-05-29 2019-12-05 Abcentra, Llc Compositions and methods for treatment of psoriasis

Also Published As

Publication number Publication date
WO2021097146A1 (en) 2021-05-20
KR20220131222A (ko) 2022-09-27
EP4058042A1 (en) 2022-09-21
US20220403013A1 (en) 2022-12-22
JP2023500409A (ja) 2023-01-05
EP4058042A4 (en) 2023-12-27
CN115003319B (zh) 2026-03-31
WO2021097146A9 (en) 2021-08-05
US12570731B2 (en) 2026-03-10
JP7722989B2 (ja) 2025-08-13
CN115003319A (zh) 2022-09-02

Similar Documents

Publication Publication Date Title
JP7842822B2 (ja) 抗ｔｒｅｍ２抗体及びその使用方法
KR102076384B1 (ko) 타우병증을 치료하는 방법
CN105339002B (zh) 治疗tau病变的方法
KR20210031645A (ko) Il-11ra 항체
CN114230663B (zh) TrkA的抗体及其应用
EP4242230A1 (en) Antibody targeting interleukin 36r, preparation method therefor, and application thereof
JP2008531608A (ja) Ｙｋｌ−４０モノクローナル抗体
EP4238989A1 (en) Anti-il5 nanoantibody and use thereof
CN116731169B (zh) 一种分拣蛋白1特异性的纳米抗体及其应用
US12570731B2 (en) Methods for treating cancer with an anti-apo B100 antibody
WO2025118472A1 (zh) 一种抗met/egfr双特异性抗体及其药物偶联物
KR20220038775A (ko) 항-인간 p40 단백질 도메인 항체 및 이의 용도
US11629186B2 (en) Anti-CCL8 antibodies and uses thereof
WO2017211313A1 (zh) 长效pcsk9特异性的结合蛋白及其应用
US20230212270A1 (en) Serum albumin binding nanobody compositions and methods for using the same
EP1387698B1 (en) Method of preventing cell death using antibodies to neural thread proteins
WO2025133322A1 (en) Cnx antigen-binding molecules
HK40090814A (zh) 靶向紧密连接蛋白18.2的抗体药物偶联物
HK40092141A (zh) 靶向紧密连接蛋白18.2的抗体药物偶联物
WO2017174017A1 (zh) 前蛋白转化酶枯草溶菌素kexin 9型的结合蛋白及其应用
CN120018858A (zh) 恶性肿瘤的诊断、预后和治疗
HK40077336A (en) Modified tff2 polypeptides
HK40014453A (en) Methods and products for preventing and/or treating metastatic cancer
HK1011697B (en) Monoclonal antibody active against cd44v6
HK1011697A1 (en) Monoclonal antibody active against cd44v6

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241024

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241024

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241024

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20241107

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20241107

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241128

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241219

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20241219

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20241219

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241219

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250424

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250430

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251022

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251022

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260511